Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

E Hamilton, V Borges, R Murthy, C Anders, D Cameron, L Carey, V Müller, G Curigliano, K Gelmon, G Hortobagy, I Krop, S Loibl, X Pivort, M Pegram, D Slamon, S Hurvitz, M Tsai, E Winer

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)OT1-02-09-OT1-02-09
JournalCancer Research
Issue number4 Supplement
Publication statusPublished - 14 Feb 2017

Cite this